(Total Views: 844)
Posted On: 08/14/2020 3:25:54 PM
Post# of 155130
As many have suggested, I suspect BP is behind the latest drop in SP.
The fact that CytoDyn showed that Leronlimab works in a population where others have failed, like Gilead for instance, should be a huge statement on the potential of this drug, and not just for Covid.
Competitors are worried about leronlimab working in mild to moderate especially if it stops progression into a severe phase, since that is where their products are positioned to target.
And they are likely sweating bullets at the upcoming data in severe covid 19 population!!
The fact that CytoDyn showed that Leronlimab works in a population where others have failed, like Gilead for instance, should be a huge statement on the potential of this drug, and not just for Covid.
Competitors are worried about leronlimab working in mild to moderate especially if it stops progression into a severe phase, since that is where their products are positioned to target.
And they are likely sweating bullets at the upcoming data in severe covid 19 population!!
(9)
(3)
